aTyr Pharma (NASDAQ:LIFE) Rating Increased to Hold at StockNews.com

StockNews.com upgraded shares of aTyr Pharma (NASDAQ:LIFE – Get Rating) from a sell rating to a hold rating in a research report sent to investors on Sunday morning.

Separately, Zacks Investment Research upgraded shares of aTyr Pharma from a hold rating to a buy rating and set a $6.75 price objective for the company in a report on Friday, March 25th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of Buy and an average target price of $16.59.

Shares of aTyr Pharma stock opened at $5.09 on Friday. The company’s 50 day moving average price is $5.24 and its two-hundred day moving average price is $6.95. The firm has a market capitalization of $141.48 million, a P/E ratio of -2.71 and a beta of 1.50. aTyr Pharma has a fifty-two week low of $3.50 and a fifty-two week high of $13.10.

aTyr Pharma (NASDAQ:LIFE – Get Rating) last announced its earnings results on Monday, March 14th. The biotechnology company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.03). During the same period last year, the company earned ($0.47) EPS. Research analysts expect that aTyr Pharma will post -1.47 earnings per share for the current year.

A number of hedge funds have recently made changes to their positions in the business. Dimensional Fund Advisors LP raised its position in aTyr Pharma by 1.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 226,712 shares of the biotechnology company’s stock worth $1,694,000 after acquiring an additional 2,433 shares during the period. Renaissance Technologies LLC raised its position in aTyr Pharma by 1.9% in the third quarter. Renaissance Technologies LLC now owns 179,655 shares of the biotechnology company’s stock worth $1,631,000 after acquiring an additional 3,400 shares during the period. Charles Schwab Investment Management Inc. bought a new stake in aTyr Pharma in the fourth quarter worth about $75,000. Sheaff Brock Investment Advisors LLC bought a new stake in aTyr Pharma in the third quarter worth about $100,000. Finally, Qube Research & Technologies Ltd bought a new stake in aTyr Pharma in the fourth quarter worth about $87,000. 72.15% of the stock is currently owned by institutional investors and hedge funds.

About aTyr Pharma (Get Rating)

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel immunological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1(3). The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Featured Stories